Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Discontinuing Acetylsalicylic Acid vs Continued Use in Patients ≥ 65 Years with Stable Chronic Coronary Syndrome

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial focuses on people older than 65 who have stable chronic coronary syndrome, a condition that includes a history of ischemic heart disease such as previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. The medication being studied is low‑dose aspirin, which is commonly used to help prevent new heart problems.

The purpose of the study is to determine whether stopping long‑term aspirin in this population is not worse than continuing it for overall health outcomes. Participants will be randomly assigned to either keep taking aspirin or to receive a harmless tablet that looks the same but contains no active drug (placebo). The study will follow participants for several years, checking in at regular intervals.

During the follow‑up, researchers will record events such as cardiovascular death, fatal bleeding, intracranial bleeding, ischemic stroke, MI and other serious bleeding problems, as well as less severe issues like peptic ulcer, angina, and overall quality of life. The information collected will help decide if stopping aspirin is a safe option for older adults with stable heart disease.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline assessment

    After joining, you attend an initial visit where health information is recorded, including heart condition history and current medicines.

    A physical exam, blood tests, and an electrocardiogram may be performed to document the current status.

  2. Step 2

    Randomization

    Based on the information collected, you are assigned to one of two groups: continue taking aspirin or stop taking aspirin.

    The assignment is done by a computer system to ensure fairness.

  3. Step 3

    Medication instructions

    If assigned to continue, you receive magnyl dak, enterotabletter or hjertemagnyl, filmovertrukne tabletter 75 mg, each containing 150 mg of acetylsalicylic acid.

    The tablet is taken by mouth once each day.

    If assigned to stop, you are asked not to take any aspirin tablets for the duration of the study.

  4. Step 4

    Daily medication intake

    You take the tablet at the same time each day, preferably with food to reduce stomach discomfort.

    The treatment continues for the whole study period, which may last up to three years.

  5. Step 5

    Regular follow‑up visits

    You attend scheduled visits every three to six months to check health status, report any bleeding, chest pain, or other symptoms, and to collect new study medication if needed.

    During each visit, brief questionnaires about quality of life and any side effects are completed.

  6. Step 6

    Reporting adverse events

    If you notice unusual bleeding, severe stomach pain, or any new health problem, you are instructed to inform the study team immediately, usually by phone or electronic message.

  7. Step 7

    Study completion

    At the end of the study period, a final assessment is performed, including the same tests as at baseline.

    Information collected throughout the trial is used to compare outcomes between the two groups.

Who can join the trial?

4 criteria

  • Be at least 65 years old when you join the study.
  • Have a history of ischemic heart disease that caused a major heart event such as a heart attack (myocardial infarction, MI), a procedure to open a blocked artery called percutaneous coronary intervention (PCI), or heart‑bypass surgery known as coronary artery bypass grafting (CABG) that happened more than two years ago.
  • Since that heart event, you must not have had any new heart‑related problems like another heart attack, an ischemic stroke (a stroke caused by a blocked blood vessel), a transient ischemic attack (TIA) (a brief, temporary stroke‑like episode), or any repeat procedures to open or bypass heart arteries (additional PCI or CABG).
  • Currently be taking a low‑dose aspirin (150 mg or less each day), as shown by your prescription records or what you report yourself.

Who cannot join the trial?

7 criteria

  • You have ever had an ischemic stroke, which is a type of brain attack caused by a blocked blood vessel.
  • You are currently taking, or need, medicines that thin the blood such as anti‑coagulants or drugs called P2Y12‑inhibitors.
  • peripheral artery disease, which is poor blood flow in the arms or legs.
  • You have had a procedure to improve blood flow in the arms or legs, known as a revascularization procedure for peripheral artery disease.
  • You have a history of a clot forming in a heart stent (called stent thrombosis) or you have had a stent placed in the main artery of the heart (left main coronary artery).
  • contraindications) that make stopping aspirin unsafe for you.
  • You are unable to understand Danish, the language used for the study information.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Aspirin (Magnyl DAK, enteric‑coated tablet) is a low‑dose aspirin taken by mouth in a tablet that is designed to dissolve later in the intestine. It works by making the blood less likely to form clots, which helps protect people with heart disease from heart attacks and strokes. In this study the drug is given to participants who continue taking aspirin, so researchers can see how well staying on aspirin works over time. Aspirin (Hjertemagnyl, film‑coated tablet) is another low‑dose aspirin taken by mouth, but it comes as a tablet with a thin coating that helps it swallow easily. Like other aspirin, it reduces the chance of blood clots forming, which can lower the risk of heart attacks and strokes. This formulation is also used in the trial for participants who keep taking aspirin, allowing comparison with the group that stops the drug. Aspirin discontinuation (no aspirin) is the strategy of stopping long‑term aspirin use in people over 65 with stable heart disease. Participants assigned to this group stop taking any aspirin tablets, and the study looks at whether their overall health outcomes are similar to those who keep taking aspirin. This approach helps determine if it is safe to stop aspirin in older patients.

What is already known about the treatment

  • Magnyl DAK, enterotabletter

    This medication is taken by mouth as a gastro‑resistant tablet that dissolves in the intestine. Aspirin has been used for many years and is well established in medical literature and treatment guidelines. It is mainly used to help prevent heart attacks and strokes in people with coronary artery disease. The drug works by blocking the COX‑1 enzyme, which lowers the production of substances that make platelets stick together; it is classified as a non‑steroidal anti‑inflammatory drug (NSAID) with antiplatelet effects.

  • Hjertemagnyl, filmovertrukne tabletter 75 mg

    This medication is taken by mouth as a film‑coated tablet that releases the drug quickly after swallowing. Aspirin is a long‑standing medicine that appears in many clinical studies and treatment recommendations. It is used to reduce the risk of heart attacks and other cardiovascular events in patients with chronic coronary syndrome. It acts by inhibiting the COX‑1 enzyme, decreasing the formation of clot‑promoting substances, and is categorized as an antithrombotic agent within the NSAID family.

Investigated diseases

Chronic coronary syndrome - It is a long‑term condition in which the coronary arteries become narrowed, limiting blood flow to the heart muscle. Over time, the reduced blood supply can cause chest discomfort, especially during physical activity. The narrowing may slowly worsen, leading to more frequent symptoms or episodes of heart muscle injury. Some people experience sudden blockages that cause a heart attack, while others have a gradual decline in heart function. The disease often progresses silently, with symptoms becoming noticeable only when the heart’s oxygen needs increase.
Trial detailsLast updated 7 Oct 2026
Age65+ yearsPhasePhase ITrial ID2026-525442-30-00Estimated enrolment7 000 patientsSponsorOdense University Hospital

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.